P210-PAM

P210-PAM is an investigational nanoparticle-based immunotherapy designed for the treatment of atherosclerotic cardiovascular disease (ASCVD). It consists of the P210 peptide, a specific antigen derived from apolipoprotein B-100 (ApoB-100), conjugated to peptide amphiphile micelles (PAMs). The drug acts as an immune modulator by being internalized by antigen-presenting cells, which subsequently elicits T cell responses and promotes a shift in monocyte phenotypes from classic inflammatory to non-classic anti-inflammatory states. In preclinical studies, P210-PAM has demonstrated the ability to inhibit the progression of established atherosclerosis, particularly when combined with cholesterol-lowering diet changes. The therapy is being developed through a collaboration between researchers at Cedars-Sinai Medical Center and the University of Southern California.

Other names

ApoB-100 peptide nanoparticlesApoB100 peptide nanoparticlesApoB 100 peptide nanoparticlesP210-conjugated nanoparticlesP-210-conjugated nanoparticlesP 210-conjugated nanoparticles